Windlas Biotech Limited (NSE:WINDLAS)
India · Delayed Price · Currency is INR 792.70
-12.20 (-1.52%)
Feb 16, 2026, 1:12 PM IST
Windlas Biotech Revenue
Windlas Biotech had revenue of 2.33B INR in the quarter ending December 31, 2025, with 19.53% growth. This brings the company's revenue in the last twelve months to 8.68B, up 19.20% year-over-year. In the fiscal year ending March 31, 2025, Windlas Biotech had annual revenue of 7.60B with 20.43% growth.
Revenue (ttm)
8.68B
Revenue Growth
+19.20%
P/S Ratio
1.94
Revenue / Employee
6.45M
Employees
1,346
Market Cap
16.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 7.60B | 1.29B | 20.43% |
| Mar 31, 2024 | 6.31B | 1.18B | 22.97% |
| Mar 31, 2023 | 5.13B | 471.53M | 10.12% |
| Mar 31, 2022 | 4.66B | 383.28M | 8.96% |
| Mar 31, 2021 | 4.28B | 987.50M | 30.03% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.60B |
| Innova Captab | 14.97B |
| Solara Active Pharma Sciences | 12.55B |
| Orchid Pharma | 8.11B |
| RPG Life Sciences | 6.74B |
| Ind-Swift Laboratories | 5.94B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.86B |